<div class="xbrl-content">
    <h3>Annual report pursuant to Section 13 and 15(d)</h3>
    <div id="xbrl-menu-top">
        <div class="navigation">
            <ul class="xbrl-sf-menu">
                
                    <li>
                        <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2190">Cover</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2190">Document And Entity Information</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2191">Financial Statements</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2191">Consolidated Statements of Earnings and Comprehensive Income</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2192">Consolidated Balance Sheets</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2193">Consolidated Balance Sheets (Parentheticals)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2194">Consolidated Statements of Shareholders' Equity</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2195">Consolidated Statements of Cash Flows</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2196">Notes to Financial Statements</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2196">Note 1 - Description of Business and Summary of Significant Accounting Policies</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2197">Note 2 - Revenue Recognition</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2198">Note 3 - Supplemental Balance Sheet and Cash Flow Information</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2199">Note 4 - Acquisitions</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2200">Note 5 - Fair Value Measurements</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2201">Note 6 - Debt and Other Financing Arrangements</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2202">Note 7 - Leases</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2203">Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2204">Note 9 - Earnings Per Share</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2205">Note 10 - Share-based Compensation and Other Benefit Plans</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2206">Note 11 - Income Taxes</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2207">Note 12 - Segment Information</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2208">Note 13 - Subsequent Events</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2209">Accounting Policies</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2209">Significant Accounting Policies (Policies)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2210">Notes Tables</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2210">Note 2 - Revenue Recognition (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2211">Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2212">Note 4 - Acquisitions (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2213">Note 5 - Fair Value Measurements (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2214">Note 7 - Leases (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2215">Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2216">Note 9 - Earnings Per Share (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2217">Note 10 - Share-based Compensation and Other Benefit Plans (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2218">Note 11 - Income Taxes (Tables)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2219">Note 12 - Segment Information (Tables)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item current" href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2220">Notes Details</a>
                        <ul class="submenu">
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2220">Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2221">Note 2 - Revenue Recognition (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2222">Note 2 - Revenue Recognition - Disaggregation of Revenue (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2223">Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2224">Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2225">Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2226">Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2227">Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2228">Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2229">Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2230">Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2231">Note 4 - Acquisitions (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2232">Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2233">Note 5 - Fair Value Measurements (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2234">Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2235">Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2236">Note 6 - Debt and Other Financing Arrangements (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2237">Note 7 - Leases (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2238">Note 7 - Leases - Balance Sheet Classification (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2239">Note 7 - Leases - Cash Paid (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2240">Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2241">Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2242">Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2243">Note 9 - Earnings Per Share (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2244">Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2245">Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2246">Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2247">Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2248">Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2249">Note 11 - Income Taxes (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2250">Note 11 - Income Taxes - Components of Provision for Income Taxes (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2251">Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2252">Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2253">Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2254">Note 12 - Segment Information (Details Textual)</a></li>
                                                            <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/2255">Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)</a></li>
                                                    </ul>
                    </li>
                            </ul>
        </div>
    </div>
    <div class="spr-xbrl-document">
        <h4>Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)</h4>
        11a
<?xml version="1.0" encoding="UTF-8"?>
<Error><Code>InternalError</Code><Message>We encountered an internal error. Please try again.</Message><RequestId>GVEA3FWZW2M40BBK</RequestId><HostId>aqq7T6mdCgPhGeCswkxFsbK8L0uwpA5cLudQ7g2I+wBerhcj4UmRpidxQNsjgj6EpiLtwmZtjAo=</HostId></Error>
0

        <div style="clear:both;"></div>
    </div>
</div>

<link rel="stylesheet" href="//investors.bio-techne.com/stylesheets/xbrl.css" type="text/css">